Contact Us
  • Events News
1 min read

San Diego convention Center: June 22 – 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

June 22- 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

Let’s connect! #BioInternationalConvention #SanDiego #USA #AcesoTherapeutics #CysticFibrosis

  • Article details

Category

Events News

Published

June 2, 2026

Reading time

1 min read

Topic

  • Share article
  • Explore more from ACESO

Uncategorized

Research news

Recognition

Publication

Press Release

Keep reading

Related news & insights

  • Events News

Aceso Advances Complementary Peptide Approaches to Enhance CFTR Function

Vienna, Austria – September 6–11, 2026 — Aceso Therapeutics is presenting new research at the 38th European Peptide Symposium, highlighting promising advances in peptide-based approaches to address key challenges in

Read More
  • Company News, Events News, Recognition

A proud moment for the entire Aceso Therapeutics team

🏆 A proud moment for the entire Aceso Therapeutics team: ACT-101 has been selected as a winner of the 2026 i-Lab Innovation Competition (28th edition), supported by Bpifrance under the
Read More
  • Company News

SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis

Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for
Read More
Back to all news

Get in touch

Partner with us to redefine cystic fibrosis care.

Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

Request Information
Investor Relations

Email

contact@aceso-therapeutics.com

Headquarters

Montpellier, France